ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

13 links0 made here, not in the record25 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05934331A LM-302 Combination WithOther Anti-Tumor TherapiesPhase ll StudyLaNova Medicines Zhejiang Co.,Phase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 19 · ClinicalTrials.gov record · Version of 2026-10-19Version of 2026-10-19CONDITIONSMalignant Neoplasms of Dige…No longer in the registry's filing›Nov 14 · Rule based · Not readNot readDRUGSTecotabart vedotinEntry “LM-302”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedToripalimabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCapecitabineIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundTegafurEntry “Tegafur, Gimeracil and Oteraci…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundGimeracilEntry “Tegafur, Gimeracil and Oteraci…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundINT004690Entry “Tegafur, Gimeracil and Oteraci…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerApatinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundGemcitabineIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundTislelizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundAnlotinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundBenmelstobartIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Tecotabart vedotin

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “LM-302”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Oct 19The record itselfClinicalTrials.gov recordVersion of 2026-10-19Record change
Nov 2Tecotabart vedotinClaude Opus 5.5TestedCurrent
Nov 2ToripalimabClaude Opus 5.5BackgroundCurrent
Nov 2CapecitabineClaude Opus 5.5BackgroundCurrent
Nov 2TegafurClaude Opus 5.5BackgroundCurrent
Nov 2GimeracilClaude Opus 5.5BackgroundCurrent
Nov 2INT004690Claude Opus 5.5BackgroundCurrent
Nov 2NivolumabClaude Opus 5.5Background · partnerCurrent
Nov 2ApatinibClaude Opus 5.5BackgroundCurrent
Nov 2GemcitabineClaude Opus 5.5BackgroundCurrent
Nov 2TislelizumabClaude Opus 5.5BackgroundCurrent
Nov 2AnlotinibClaude Opus 5.5BackgroundCurrent
Nov 2BenmelstobartClaude Opus 5.5BackgroundCurrent
Nov 14Malignant Neoplasms of Digestive OrgansRule based · condition-kind ruleNot readCurrent
Nov 18Tecotabart vedotinRule based · role ruleTestedAgrees
Nov 18ToripalimabRule based · role ruleBackgroundAgrees
Nov 18CapecitabineRule based · role ruleBackgroundAgrees
Nov 18TegafurRule based · role ruleBackgroundAgrees
Nov 18GimeracilRule based · role ruleBackgroundAgrees
Nov 18INT004690Rule based · role ruleBackgroundAgrees
Nov 18NivolumabRule based · role ruleBackgroundAgrees
Nov 18ApatinibRule based · role ruleBackgroundAgrees
Nov 18GemcitabineRule based · role ruleBackgroundAgrees
Nov 18TislelizumabRule based · role ruleBackgroundAgrees
Nov 18AnlotinibRule based · role ruleBackgroundAgrees
Nov 18BenmelstobartRule based · role ruleBackgroundAgrees

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.